U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H21FN4O2
Molecular Weight 368.4055
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AB-FUBINACA

SMILES

CC(C)[C@@]([H])(C(=N)O)NC(=O)c1c2ccccc2n(Cc3ccc(cc3)F)n1

InChI

InChIKey=AKOOIMKXADOPDA-KRWDZBQOSA-N
InChI=1S/C20H21FN4O2/c1-12(2)17(19(22)26)23-20(27)18-15-5-3-4-6-16(15)25(24-18)11-13-7-9-14(21)10-8-13/h3-10,12,17H,11H2,1-2H3,(H2,22,26)(H,23,27)/t17-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H21FN4O2
Molecular Weight 368.4055
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27632803

AB‐FUBINACA is a synthetic cannabinoid and it is a very potent agonist for the cannabinoid (CB1) receptor. AB-FUBINACA is designated as a Schedule I controlled substance in the United States.

Originator

Curator's Comment:: It was originally developed by Pfizer in 2009 as an potential therapeutic agent, but was never pursued for human use. # Pfizer Inc.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.1 nM [EC50]
0.9 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome.
2014 Jun
Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market.
2015 Aug
Synthetic cannabimimetic agents metabolized by carboxylesterases.
2015 Jul
Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.
2015 Sep 16
Schedules of Controlled Substances: Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA into Schedule I. Final rule.
2016 Sep 6
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
AB‐FUBINACA is a very potent ligand for the cannabinoid (CB1) receptor, with a Ki of 0.9 nM and an EC50 of 23.2 nM for receptor activation as measured by GTPgammaS hydrolysis.
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:24:45 UTC 2021
Edited
by admin
on Sat Jun 26 16:24:45 UTC 2021
Record UNII
I7PZF0KTFK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AB-FUBINACA
Common Name English
N-((1S)-1-(AMINOCARBONYL)-2-METHYLPROPYL)-1-((4-FLUOROPHENYL)METHYL)-1H-INDAZOLE-3-CARBOXAMIDE
Systematic Name English
DEA NO. 7012
Code English
1H-INDAZOLE-3-CARBOXAMIDE, N-((1S)-1-(AMINOCARBONYL)-2-METHYLPROPYL)-1-((4-FLUOROPHENYL)METHYL)-
Systematic Name English
Classification Tree Code System Code
DEA NO. 7012
Created by admin on Sat Jun 26 16:24:45 UTC 2021 , Edited by admin on Sat Jun 26 16:24:45 UTC 2021
Code System Code Type Description
EPA CompTox
1185282-01-2
Created by admin on Sat Jun 26 16:24:45 UTC 2021 , Edited by admin on Sat Jun 26 16:24:45 UTC 2021
PRIMARY
PUBCHEM
58124325
Created by admin on Sat Jun 26 16:24:45 UTC 2021 , Edited by admin on Sat Jun 26 16:24:45 UTC 2021
PRIMARY
CAS
1185282-01-2
Created by admin on Sat Jun 26 16:24:45 UTC 2021 , Edited by admin on Sat Jun 26 16:24:45 UTC 2021
PRIMARY
WIKIPEDIA
AB-FUBINACA
Created by admin on Sat Jun 26 16:24:45 UTC 2021 , Edited by admin on Sat Jun 26 16:24:45 UTC 2021
PRIMARY
CAS
1629062-56-1
Created by admin on Sat Jun 26 16:24:45 UTC 2021 , Edited by admin on Sat Jun 26 16:24:45 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY
FDA UNII
I7PZF0KTFK
Created by admin on Sat Jun 26 16:24:45 UTC 2021 , Edited by admin on Sat Jun 26 16:24:45 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
EC50
TARGET -> AGONIST
EC50
Related Record Type Details
ACTIVE MOIETY